Last edition
News about "Non-Small Cell Lung Cancer (NSCLC) "
AstraZeneca Enters into Global License Agreement with with Dizal Pharmaceutical for Zegfrovy
AstraZeneca has entered a global licensing agreement with Dizal Pharmaceutical for Zegfrovy, expanding its EGFR-targeted lung cancer portfolio.
Non-Small Cell Lung Cancer (NSCLC) | 15/07/2026 | By News Bureau
Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial
Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).
Non-Small Cell Lung Cancer (NSCLC) | 02/07/2026 | By News Bureau | 102
GSK Enters Agreement to Acquire Nuvalent
GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.
Non-Small Cell Lung Cancer (NSCLC) | 10/06/2026 | By News Bureau | 257
US FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC
Calderasib has received US FDA Breakthrough Therapy Designation for certain patients with newly diagnosed metastatic KRAS G12C-mutant Non-Small Cell Lung Cancer (NSCLC), supported by promising phase 1 KANDLELIT-001 trial data highlighting its potential as a next-generation, highly potent and selective KRAS G12C inhibitor.
Non-Small Cell Lung Cancer (NSCLC) | 30/05/2026 | By News Bureau | 136
Bayer Secures Breakthrough Status for Sevabertinib in HER2 NSCLC
US FDA and China’s CDE granted the designation for sevabertinib as a potential first-line therapy in advanced HER2-mutant non-small cell lung cancer.
Non-Small Cell Lung Cancer (NSCLC) | 07/01/2026 | By News Bureau | 357
Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma
Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.
Non-Small Cell Lung Cancer (NSCLC) | 17/12/2025 | By News Bureau | 252
Radiopharm Theranostics Begins Enrollment for Third Cohort in Phase 1 Trial of 177Lu-RAD204
Radiopharm Theranostics has opened enrollment for the third cohort of its Phase 1 dose-escalation trial of 177Lu-RAD204, after the Data Safety Monitoring Committee cleared escalation to a 90 mCi dose. Early results from the first two cohorts show tumour uptake and a favourable safety profile.
Non-Small Cell Lung Cancer (NSCLC) | 15/11/2025 | By Dineshwori
Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC
Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.
Non-Small Cell Lung Cancer (NSCLC) | 24/10/2025 | By Dineshwori | 365
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy